The Dosage Exploration Study of PEG-rhGH for Treating Short Stature in Prepubertal and Pubertal Children

ConditionShort Stature
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age1-16
SponsorSecond Affiliated Hospital of Wenzhou Medical University

About this trial

This study is dedicated to addressing the lack of research on the most effective dosage of long-acting growth hormone for children with short stature. By employing clinical trial design, we are committed to investigating the therapeutic benefits and safety profiles associated with varying doses of long-acting growth hormone. Our ultimate goal is to offer clinicians more precise treatment guidance and assist patients in attaining optimal growth and developmental outcomes.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients with short stature or a genetic target height below 2 standard deviations;

Individuals who are pre-pubertal (Tanner stage I) and pubertal (Tanner stages II-IV).

Legal guardians consenting to participate in the study and signing informed consent forms.

Disqualifiers

Known or suspected hypersensitivity reactions to the investigational product or related products;

Presence of severe systemic diseases;

Patients with malignant tumors;

Participation in any other clinical trial and receipt of drug or non-drug interventions within the 3 months prior to screening;

Trial design

Design model

Parallel

Treatments tested in this trial

  • PEG-rhGH

    Drug

    1= 0.2mg/kg/week Initial doses of PEG-rhGH 2=0.22mg/kg/week Initial doses of PEG-rhGH

  • GnRHa

    Drug

    1. pubertal children of short stature without GnRHa treatment 2. pubertal children of short stature with GnRHa treatment

Treatment groups

240 Participants
are divided into 2 treatment groups
Group A: prepubertal children of short statureOther 1 intervention
Group B: pubertal children of short statureOther 2 interventions

Trial outcomes

Primary outcomes

1

height growth rate

Measure the height and observe how many centimeters it grows each month

Time frame
2 years

Secondary outcomes

1

Sexual development status

Evaluate Tanner staging, The Tanner Staging, also known as Sexual Maturity Rating (SMR), is a classification system that healthcare providers use to document and track the development of secondary sex characteristics of children during puberty. It's a tool that outlines the stages of puberty for children and when they're likely to occur.

Time frame
two years
2

IGF-1

IGF-1, known as insulin-like growth factor, is utilized to evaluate the efficacy of growth hormone therapy. By measuring IGF-1 levels, doctors can determine the effectiveness of the treatment and whether the patient's growth falls within the normal range

Time frame
two years

Other outcomes

1

bone age

Bone age assessment

Time frame
2 years

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: